sulfinpyrazone has been researched along with Obesity in 2 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| EHRENBOECK, R | 1 |
| Klotz, H | 1 |
| Prohaska, E | 1 |
| Salmhofer, H | 1 |
| Schmid, L | 1 |
2 other studies available for sulfinpyrazone and Obesity
| Article | Year |
|---|---|
[GOUT AND ITS TREATMENT WITH ANTURANE].
Topics: Arthritis; Arthritis, Rheumatoid; Blood; Diabetes Mellitus; Drug Therapy; Gout; Humans; Obesity; Sul | 1965 |
[Gout from the view of a special hospital for rheumatic patients].
Topics: Acute Disease; Adolescent; Adult; Aged; Austria; Child; Cholesterol; Colchicine; Colic; Diabetes Com | 1971 |